MorphoSys and Sigma-Aldrich Enter into Collaboration and Licensing Agreement for Recombinant Research Antibodies
News Feb 28, 2008
MorphoSys's AbD Serotec unit will develop and qualify antibodies from MorphoSys's proprietary HuCAL GOLD library against a committed number of targets identified and supplied by Sigma-Aldrich. HuCAL GOLD is the powerful phage-display library developed for the in vitro generation of highly specific and fully human antibodies.
The large diversity of the library guarantees fast and successful generation of high-quality antibodies to targets that have previously been difficult to probe with standard antibody-generation technologies.
Sigma-Aldrich will offer the HuCAL-based recombinant research antibodies for use in research applications through its online sales platforms Antibody Explorer™ and Your Favorite Gene Search™.
"We are very excited about the potential of this partnership," said Dr. David Smoller, president of Sigma-Aldrich's Research Biotech business unit. "HuCAL-based recombinant antibody technology will allow researchers access to antibody content not available through standard antibody generation technologies. In conjunction with Sigma-Aldrich's standard content generation capabilities, this powerful technology is expected to allow the community to reach its goal of a binder for every gene and one-day even protein in the human body."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.